FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... March 25, 2021 How International Collaboration Has Helped Improve Cancer Care in Nepal April 8, 2021 What to Know About Biomarker Testing for Lung Cancer: An Expert... June 9, 2022 Breast Cancer Survivor Thanks Early Detection For Saving Her Life April 6, 2021 Load more HOT NEWS Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable... ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... Study Offers Insights on Health Problems among AYA Cancer Survivors
